GWPH
GW Pharmaceuticals plc

13,509
Loading...
Loading...
GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of GW Pharmaceuticals - ADR?
What is the 52-week high for GW Pharmaceuticals - ADR?
What is the 52-week low for GW Pharmaceuticals - ADR?
What is GW Pharmaceuticals - ADR stock price today?
What was GW Pharmaceuticals - ADR stock price yesterday?
What is the PE ratio of GW Pharmaceuticals - ADR?
What is the Price-to-Book ratio of GW Pharmaceuticals - ADR?
What is the 50-day moving average of GW Pharmaceuticals - ADR?

Latest GWPH News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.